Program Schedule

Sunday, November 11
7:45 am – 8:30 am Registration Open
8:00 am – 8:05 am Announcements
Robert Zimmerman, SD
Bayer Pharmaceutical Division
8:05 am – 11:10 am New Agents in Development
Co-Chairs:
Ronald Bukowski, MD
Cleveland ClinicAlexander Eggermont, MD, PhD
Rotterdam Cancer Institute
8:05 am – 8:30 am Thalidomide and its Successor Molecules as Agents for Biological Therapy
Jerry Zeldis, MD, PhD
Celgene Corporation
8:30 am – 8:55 am From Coley’s Toxins to CpG DNA: Immunotherapy with CpG Motifs From Bacterial DNA
Arthur M. Krieg, MD
Coley Pharmaceutical Group
8:55 am – 9:20 am Supression of BCL-2 Gene Expression by Targeted Disruption of RNA
Burkhard Jansen, MD
University of Vienna
9:20 am – 9:40 am Break
9:40 am – 9:55 am ANGIOZYME, a Synthetic Ribozyme Targeting the mRNA of VEGFR-1:Clinical Update
David Wang, MD, PhD
Cleveland Clinic
9:55 am – 10:10 am Pharmacokinetics in Beagle Dogs and Cynomologus Monkeys, of VNP20009, an Attenuated Salmonella Typhimurium for the Treatment of Cancer
Caroline Clairmont, PhD
Vion Pharmaceuticals, Inc.
10:10 am – 10:25 am A Phase 2 Trial To Evaluate the Rate of Immune Response Using Recombinant Idiotype for Treatment of Follicular Non- Hodgkin’s Lymphoma
Lori Kunkel, MD
Genitope Corporation
10:25 am – 10:40 am Shikonin, a Small Molecule Compound from Chinese Herbal Medicine with Anti- inflammatory and Anti-HIV-1 Activity, is an Inhibitor of Multiple Chemokine Receptors
Xin Chen, MD, PhD
Center for Cancer Research
National Cancer Institute
10:40 am – 10:55 am TRAIL Induced Apoptosis of Human Melanoma is Regulated by Smac/DIABLO Release from Mitochondria
Peter Hersey MD, PhD
Royal Newcastle Hospital
10:55 am – 11:10 am The Proteasome Inhibitor PS-341 Sensitizes Tumor Cells to TRAIL-mediated Lysis
Thomas J. Sayers, PhD
Center for Cancer Research
National Cancer Institute
11:10 am – 11:25 am Closing Comments
Robert O. Dillman, MD
President, SBT